Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADHD Drug Safety In Adults Still Under Review After FDA Gives Kids Cardiac Thumbs Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Observational study sponsored by FDA and AHRQ showed no association between the use of certain ADHD medications and CV events in children.

You may also be interested in...

FDA Urges Calm After Stimulants Linked To Sudden Death

Agency awaits two additional observational studies after acknowledging that a study it funded has methodological flaws.

ADHD Drug Makers To Include Patient Medication Guides To Warn Of Cardiovascular, Psychiatric Risks

Manufacturers have 30 days to comply with FDA's request, Division of Psychiatry Products Director Laughren says.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts